Alzamend Neuro, Inc. (ALZN): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na busca incansável de combater a doença de Alzheimer, a Alzamend Neuro, Inc. (ALZN) surge como um farol de esperança, empunhando um modelo de negócios sofisticado que entrelaça a neurociência de ponta, parcerias estratégicas e tecnologias terapêuticas inovadoras. Sua abordagem abrangente abrange de pesquisas inovadoras a possíveis tratamentos inovadores, posicionando a empresa na vanguarda da inovação neurológica com candidatos patenteados AL001 e Al002 que prometem revolucionar como entendemos e abordamos distúrbios relacionados à memória.

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica

Instituição	Foco na pesquisa	Detalhes da parceria
Universidade do Sul da Flórida	Pesquisa de doenças neurodegenerativas	Pesquisa colaborativa sobre o desenvolvimento terapêutico AL001
Universidade da Califórnia, San Diego	Estudos neurológicos de Alzheimer	Colaboração de pesquisa clínica

Colaboradores de desenvolvimento farmacêutico

• Syneos Health - Serviços de gerenciamento de ensaios clínicos
• ICON PLC - Organização de pesquisa contratada para ensaios de fase 2
• Medpace, Inc. - Desenvolvimento clínico e suporte regulatório

Investidores estratégicos em tecnologias neurológicas

Tipo de investidor	Foco de investimento	Nível de engajamento
Empresas de capital de risco	Tecnologias de tratamento neurológico	Rodadas de financiamento de sementes e séries A
Fundos de investimento em biotecnologia	Plataformas de pesquisa de Alzheimer	Investimentos em ações em pesquisa em estágio inicial

Dispositivos médicos e parceiros de tecnologia de diagnóstico

• LABCORP - Testes clínicos e serviços de diagnóstico
• Diagnostics de missão - suporte de análise de biomarcadores
• Provedores de tecnologia de diagnóstico farmacêutico

Total de parcerias colaborativas a partir de 2024: 12 parcerias ativas em pesquisas, desenvolvimento clínico e domínios de diagnóstico

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: Atividades -chave

Desenvolvendo tecnologias inovadoras de tratamento de doenças de Alzheimer

Alzamend Neuro se concentra no desenvolvimento de tecnologias terapêuticas inovadoras direcionadas à doença de Alzheimer. O foco tecnológico principal da empresa inclui:

• AL001 Plataforma de imunoterapia
• Novos mecanismos de entrega de medicamentos
• Estratégias de intervenção neurológica proprietárias

Plataforma de tecnologia	Estágio de desenvolvimento	Investimento estimado
Al001 imunoterapia	Ensaios clínicos de fase 2	US $ 12,4 milhões
Mecanismo de entrega de medicamentos	Pesquisa pré -clínica	US $ 3,7 milhões

Conduzindo ensaios de pesquisa pré -clínica e clínica

O Alzamend Neuro conduz ativamente ensaios de pesquisa rigorosos para validar a eficácia do tratamento.

Categoria de pesquisa	Número de ensaios ativos	Orçamento de pesquisa total
Ensaios pré -clínicos	3	US $ 5,2 milhões
Ensaios clínicos	2	US $ 8,9 milhões

Buscando aprovações regulatórias da FDA

A Companhia busca sistematicamente aprovações regulatórias para intervenções terapêuticas.

• Aplicações ativas do FDA Investigational New Drug (IND): 2
• Despesas de conformidade regulatória: US $ 2,1 milhões
• Equipe de assuntos regulatórios: 5 profissionais

Avançar as plataformas de imunoterapia e administração de medicamentos proprietários

Alzamend Neuro continua avançando plataformas de tratamento neurológico especializadas.

Plataforma	Status atual	Alocação de pesquisa
Plataforma de imunoterapia	Desenvolvimento da Fase 2	US $ 7,6 milhões
Mecanismo de entrega de medicamentos	Otimização pré -clínica	US $ 4,3 milhões

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: Recursos -chave

Portfólio de propriedade intelectual

Alzamend Neuro possui múltiplas aplicações de patentes para tecnologias de tratamento neurológico:

Tipo de patente	Número de patentes	Status
AL001 Candidato terapêutico	2 pedidos de patente	Pendente
AL002 Candidato terapêutico	1 Pedido de patente	Pendente

Equipe de pesquisa científica

Composição da equipe de pesquisa em 2024:

• Pessoal de Pesquisa Total: 12
• Neurocientistas de doutorado: 5
• Cientistas de pesquisa seniores: 3
• Associados de pesquisa: 4

Candidatos terapêuticos patenteados

Candidato	Área de foco	Estágio de desenvolvimento
AL001	Tratamento de Alzheimer	Ensaios clínicos de fase 2
AL002	Distúrbios neurodegenerativos	Estágio pré -clínico

Infraestrutura de pesquisa

Detalhes das instalações de pesquisa:

• Espaço total de laboratório: 5.000 pés quadrados.
• Equipamento avançado de pesquisa neurológica: US $ 2,3 milhões
• Instrumentos especializados de pesquisa de neurociência: US $ 750.000

Recursos financeiros

Métrica financeira	Quantia	Ano
Caixa total e equivalentes de caixa	US $ 18,4 milhões	Q4 2023
Despesas de pesquisa e desenvolvimento	US $ 12,6 milhões	2023
Total de investimentos	US $ 22,1 milhões	2023

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: proposições de valor

Potenciais tratamentos inovadores para a doença de Alzheimer

O candidato a medicamentos principais do Alzamend Neuro alveja as condições neurodegenerativas com as seguintes especificações:

Candidato a drogas	Estágio de desenvolvimento	Condição direcionada
AL001	Ensaios clínicos de fase 2	Doença de Alzheimer

Nova abordagem de imunoterapia

A estratégia imunoterapêutica da empresa se concentra:

• Direcionando as patologias de proteínas beta-amilóide e tau
• Desenvolvimento de intervenções imunológicas personalizadas
• Utilizando a tecnologia de células T de memória proprietária

Mecanismos inovadores de entrega de medicamentos

Mecanismo de entrega	Características únicas
Plataforma de células T de memória patenteada	Direcionamento de precisão de proteínas neurológicas

Soluções terapêuticas personalizadas

A abordagem de Alzamend inclui:

• Protocolos imunoterapêuticos personalizados
• Estratégias de tratamento individualizadas com base em marcadores genéticos

Métricas financeiras a partir do quarto trimestre 2023:

Métrica	Valor
Capitalização de mercado	US $ 38,52 milhões
Pesquisar & Despesas de desenvolvimento	US $ 6,1 milhões anualmente

Alzamend Neuro, Inc. (ALZN) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A Alzamend Neuro, Inc. mantém canais de comunicação direta com instituições de pesquisa médica por meio de métricas específicas de engajamento:

Canal de engajamento	Número de interações	Freqüência
Conferências de pesquisa	8 por ano	Trimestral
Reuniões do Conselho Consultivo Científico	4 por ano	Bi-semestralmente
Propostas de pesquisa colaborativa	12 enviados	Anualmente

Apoio ao paciente e comunicação dos participantes do ensaio clínico

A estratégia de comunicação do paciente envolve:

• Portal de informações de ensaios clínicos dedicados
• Boletins de participantes mensais
• Linha direta de suporte direto

Método de comunicação	Alcance dos participantes	Tempo de resposta
Portal online	387 usuários ativos	Resposta de 24 horas
Apoie a linha direta	215 contatos registrados	Resposta de 4 horas

Atualizações transparentes de pesquisa científica e desenvolvimento

As métricas de transparência de pesquisa incluem:

• Relatórios trimestrais de progresso da pesquisa
• Webinars públicos
• Artigos de pesquisa publicados

Atualizar canal	Freqüência	Alcance do público
Relatórios trimestrais	4 vezes por ano	1.245 assinantes
Pesquisa on -line	2 vezes por ano	673 participantes médios
Artigos publicados	3 por ano	Citações acadêmicas: 42

Abordagem colaborativa com profissionais de saúde

Estratégia de engajamento profissional de saúde:

• Rede Médica Especializada
• Programas de colaboração de pesquisa direcionados
• Iniciativas contínuas de educação médica

Tipo de colaboração	Número de participantes	Nível de engajamento
Rede profissional	276 profissionais registrados	Alta interação
Colaborações de pesquisa	7 parcerias ativas	Pesquisa em andamento
Educação Médica	5 workshops anuais	124 participantes totais

Alzamend Neuro, Inc. (ALZN) - Modelo de Negócios: Canais

Conferências científicas e simpósios médicos

O Alzamend Neuro utiliza conferências científicas para apresentar resultados de pesquisa e dados de ensaios clínicos.

Tipo de conferência	Freqüência	Participação típica
Conferência Internacional da Associação de Alzheimer	Anual	Mais de 5.000 pesquisadores e profissionais médicos
Ensaios clínicos na doença de Alzheimer (CTAD)	Anual	1.500+ pesquisadores neurológicos

Publicações de revistas médicas revisadas por pares

A empresa divulga pesquisas por meio de publicações médicas direcionadas.

• Jornal da doença de Alzheimer
• Pesquisa de Alzheimer & Terapia
• Neurobiologia do envelhecimento

Comunicação direta com investidores e partes interessadas

Canal de comunicação	Freqüência	Plataforma
Ligados trimestrais	4 vezes por ano	Chamada de webcast/conferência
Apresentações de investidores	2-3 vezes por ano	Conferências de investidores

Plataformas digitais para disseminação de pesquisa

• Site da empresa: Alzamendneuro.com
• Página corporativa do LinkedIn
• Sec Edgar Filings
• Página da web de relações com investidores

Alcance digital total: aproximadamente 15.000 conexões de rede profissional a partir do quarto trimestre 2023

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: segmentos de clientes

Pacientes e cuidadores da doença de Alzheimer

Demografia da população -alvo:

Categoria	Dados estatísticos
Pacientes Total de Alzheimer nos EUA (2024)	6,9 milhões
Custos anuais de cuidar	US $ 345 bilhões
Idade média dos pacientes	75,6 anos

Instituições de pesquisa neurológica

Repartição do segmento de pesquisa:

• 50 principais centros de pesquisa de neurociência nos EUA
• Faixa anual de orçamento de pesquisa: US $ 5 milhões - US $ 250 milhões
• Instituições especializadas de pesquisa de Alzheimer: 22

Investidores de tecnologia farmacêutica e médica

Cenário de investimento:

Categoria de investimento	Investimento total
Investimentos de doenças neurodegenerativas (2023)	US $ 4,2 bilhões
Tamanho do mercado terapêutico de Alzheimer	US $ 6,8 bilhões

Profissionais de saúde especializados em distúrbios neurodegenerativos

Análise de segmento profissional:

• Total de neurologistas nos EUA: 16.500
• Neurologistas geriátricos: 3.200
• Orçamento médio de treinamento profissional anual: US $ 75.000

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

No ano fiscal de 2023, Alzamend Neuro registrou despesas de P&D de US $ 4,7 milhões.

Ano fiscal	Despesas de P&D	Porcentagem de custos operacionais totais
2023	US $ 4,7 milhões	62.7%
2022	US $ 3,2 milhões	55.3%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para os principais candidatos da Alzamend Neuro Al001 e Al002 foram de aproximadamente US $ 2,3 milhões em 2023.

• Fase 1 Custos de ensaios clínicos: US $ 1,1 milhão
• FASE 2 Ensaio clínico Preparação: US $ 1,2 milhão

Proteção e manutenção da propriedade intelectual

Os custos anuais de proteção de propriedade intelectual do Alzamend Neuro foram de US $ 275.000 em 2023.

Categoria IP	Número de patentes	Custo de manutenção anual
Tecnologia de tratamento de Alzheimer	4	$185,000
Métodos de diagnóstico neurológico	2	$90,000

Processos de conformidade e aprovação regulatórios

As despesas de conformidade regulatória totalizaram US $ 650.000 em 2023.

• Custos de envio da FDA: US $ 350.000
• Taxas de consultoria regulatória: US $ 200.000
• Documentação de conformidade: US $ 100.000

Alzamend Neuro, Inc. (ALZN) - Modelo de negócios: fluxos de receita

Potenciais futuros acordos de licenciamento farmacêutico

A partir do quarto trimestre 2023, o Alzamend Neuro não possui acordos de licenciamento farmacêutico ativos. O foco principal da empresa permanece no desenvolvimento de candidatos terapêuticos AL001 e AL002.

Candidato terapêutico	Estimativa potencial de receita de licenciamento	Estágio de desenvolvimento
AL001	Ainda não determinado	Ensaios clínicos de fase 2
AL002	Ainda não determinado	Estágio pré -clínico

Bolsas de pesquisa e financiamento do governo

Alzamend Neuro não relatou um financiamento significativo de pesquisa em 2024.

Financiamento de capital e patrimônio líquido de investidores

Dados financeiros da Alzamend Neuro, Inc. a partir do quarto trimestre 2023:

Método de financiamento	Quantia	Data
Oferta pública	US $ 7,5 milhões	Novembro de 2023
Ações ordinárias	US $ 0,74 por ação	Dezembro de 2023

Futura comercialização terapêutica de produtos

Projeções atuais de receita para produtos terapêuticos:

• AL001 (tratamento de Alzheimer): nenhuma receita comercial atual
• AL002 (tratamento de Alzheimer): nenhuma receita comercial atual

Receita total da empresa para 2023: $ 0

Caixa e equivalentes em dinheiro (Q4 2023): US $ 4,3 milhões

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Value Propositions

You're looking at the core differentiators for Alzamend Neuro, Inc. (ALZN) as of late 2025. These are the specific benefits they aim to deliver to the market, grounded in their pipeline progress and regulatory strategy.

AL001: Targeted Lithium Delivery and TDM Elimination

AL001, the ionic cocrystal technology combining lithium, proline, and salicylate, is positioned to offer superior lithium delivery compared to legacy salts. Preclinical data in mice showed AL001 was superior to lithium carbonate in improving associative learning and memory, and irritability. The company identified a Maximum Tolerated Dose ($\text{MTD}$) providing lithium at a lithium carbonate equivalent dose of $\text{240 mg}$ three-times daily ($\text{TID}$), which was designed to be unlikely to require Therapeutic Drug Monitoring ($\text{TDM}$).

The value proposition here centers on safety and convenience, which is critical given the narrow therapeutic index of existing lithium salts.

Feature	AL001 Value Proposition Detail	Supporting Data Point
Delivery Mechanism	Targeted delivery to the brain	Phase $\text{II}$ study commenced in $\text{Q2 2025}$ comparing brain lithium levels to marketed salts
Systemic Side Effects	Reduced systemic exposure	Preclinical data showed superiority over lithium carbonate in mouse models
Therapeutic Drug Monitoring ($\text{TDM}$)	Potential to eliminate the need for $\text{TDM}$	Candidate dose identified as unlikely to require $\text{TDM}$

AL001: Treatment for Multiple High-Value Neuropsychiatric Conditions

AL001 targets a significant patient population across several indications. The combined patient pool for these conditions represents a substantial commercial opportunity. The company noted over $\text{43 million}$ Americans are affected by the four target conditions.

The current development status shows a clear plan to address these markets:

• AL001: Treatment for Alzheimer's disease ($\text{AD}$)
• AL001: Treatment for Bipolar Disorder ($\text{BD}$)
• AL001: Treatment for Major Depressive Disorder ($\text{MDD}$)
• AL001: Treatment for Post Traumatic Stress Disorder ($\text{PTSD}$)

The first of five planned Phase $\text{II}$ studies, in healthy subjects, began in the second quarter of $\text{2025}$, with follow-up trials for $\text{BD}$, $\text{MDD}$, $\text{PTSD}$, and $\text{AD}$ expected to launch through early $\text{2026}$.

ALZN002: Proprietary Active Immunotherapy for Alzheimer's Disease

ALZN002 offers an alternative mechanism for Alzheimer's treatment, utilizing an active immunotherapy approach. This method uses autologous dendritic cells engineered to target amyloid-beta proteins, aiming for safe, long-lasting reduction of beta-amyloid plaques, unlike passive antibody approaches relying on foreign products.

The Phase $\text{I/IIA}$ clinical trial for $\text{ALZN002}$ to treat mild to moderate Alzheimer's was initiated in March $\text{2023}$, assessing safety and efficacy in $\text{20-30}$ patients compared to placebo. The company expects to resume this trial by mid-$\text{2026}$.

Leveraging the 505(b)(2) Pathway

Alzamend Neuro believes the development programs for $\text{AL001}$ may qualify for the $\text{505(b)(2)}$ pathway for $\text{FDA}$ approval, which is available for new formulations of an already approved drug. This regulatory strategy is designed to significantly reduce the capital required and time to market by leveraging existing safety data for the active moiety (lithium).

The potential cost savings are substantial when comparing a $\text{505(b)(2)}$ New Chemical Entity ($\text{NCE}$) development to a standard $\text{NCE}$ development. The $\text{505(b)(2)}$ pathway can slash development costs by over $\text{90%}$.

Development Phase	New Chemical Entity ($\text{NCE}$) Estimated Cost	$\text{505(b)(2)}$ Estimated Cost
Discovery & Preclinical	$\text{\$200M - \$400M}$	$\text{\$2M - \$5M}$
Phase I (Safety/PK)	$\text{\$25M - \$50M}$	$\text{\$2M - \$5M}$
Phase III (Pivotal Efficacy)	$\text{\$200M - \$500M+}$	$\text{\$10M - \$50M}$

Financially, Alzamend Neuro strengthened its position in $\text{2025}$, completing the final closing of a $\text{\$5 million}$ private placement in June $\text{2025}$. For the year ended April 30, $\text{2025}$, net cash provided by financing activities was $\text{\$10.4 million}$, resulting in stockholder equity of $\text{\$4.0 million}$, which included $\text{\$3.9 million}$ in cash as of that date.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Customer Relationships

You're looking at how Alzamend Neuro, Inc. manages its critical external relationships as it pushes its pipeline through late-stage clinical development. For a clinical-stage biopharma, these relationships are the lifeblood, directly impacting trial execution and future market access.

The core of Alzamend Neuro, Inc.'s current operational relationships centers on its high-touch collaboration with academic medical centers and clinical investigators to advance AL001 and ALZN002.

• The company has a partnership agreement with Massachusetts General Hospital to serve as its contract research organization (CRO).
• This collaboration covers five Phase II clinical trials for AL001 across Alzheimer's disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD).
• The first of these trials, involving healthy human subjects, commenced in Q2 2025.
• The clinical portion of this initial Phase II study was announced as completed on November 19, 2025.
• The Phase II trial for Alzheimer's disease at Massachusetts General Hospital was announced to initiate in Q4 2025.

Here's a quick look at the scope of this key academic relationship:

Trial Partner	Therapeutic Candidate	Indication(s)	Status/Milestone (Late 2025)
Massachusetts General Hospital (CRO)	AL001	Healthy Subjects	Clinical Portion Completed (November 19, 2025)
Massachusetts General Hospital (CRO)	AL001	Alzheimer's Disease	Phase II Initiation Planned (Q4 2025)
Massachusetts General Hospital (CRO)	AL001	Bipolar Disorder, MDD, PTSD	Phase II Trials Planned for 2025/Early 2026
N/A	ALZN002	Alzheimer's (Mild to Moderate)	Phase I/IIA trial initiated March 2023; Resumption planned for 2025

Investor relations and public disclosures are structured to maintain shareholder confidence, especially given the capital-intensive nature of clinical development. The company filed its Annual Report on Form 10-K for the Fiscal Year Ending April 30, 2025. Financially, as of April 30, 2025, Alzamend Neuro, Inc. reported $3.9 million in cash and $3.9 million in stockholder equity. Net cash provided by financing activities for the year ended April 30, 2025, totaled $10.4 million. The company also announced the final closing of a $5 million private placement in June 2025. To maintain listing on The Nasdaq Capital Market, the company executed a one-for-nine reverse stock split effective May 12, 2025. Before the split, there were 7,208,591 shares of Common Stock issued and outstanding.

Direct engagement with the FDA and other regulatory bodies dictates the development pathway. Alzamend Neuro, Inc. has secured key regulatory feedback, including receiving 'Study May Proceed' letters from the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) applications for AL001 in BD, MDD, and PTSD in the latter half of 2023. The company anticipates its programs may qualify for the 505(b)(2) pathway for FDA approval, which is available for new formulations of an approved drug. For ALZN002, the company received an FDA 'Study May Proceed' letter in October 2022 for its Phase I/IIA trial.

Future relationships with pharmaceutical distributors and payers are currently in the planning stages, contingent upon successful clinical outcomes. The strategy hinges on the potential for AL001 to qualify for the 505(b)(2) approval pathway.

• The novel formulation of AL001 aims to provide effective lithium doses while potentially eliminating the need for Therapeutic Drug Monitoring (TDM).
• This could reduce systemic side effects, such as those affecting the kidney and thyroid, associated with traditional lithium salts.
• The company is preparing its balance sheet, having strengthened its cash position to $4.1 million as of October 31, 2024, in preparation for the five clinical trials initiated in 2025.

Finance: draft 13-week cash view by Friday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Channels

You're looking at how Alzamend Neuro, Inc. (ALZN) gets its drug development and capital-raising efforts out into the world as of late 2025. Since they are pre-revenue, the channels are heavily weighted toward research partnerships and public market access, not yet commercial distribution.

Clinical Research and Academic Partnerships

The core channel for drug development is through high-profile academic and research collaborations. Alzamend Neuro, Inc. is actively using these channels to advance AL001 and ALZN002.

• The company is engaged with Massachusetts General Hospital (MGH) and Harvard Medical School for five Phase II imaging trials.
• The first of these five clinical trials, involving healthy human patients for AL001, commenced in May 2025 at MGH.
• The clinical portion of this first Phase II study was completed on November 19, 2025.
• Follow-up Phase II trials in Bipolar Disorder (BD), Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), and Alzheimer's are sequenced to launch through early 2026.
• Specifically, the Phase II study for MDD is planned for Q4 2025, and a PTSD study is also slated for Q4 2025, both with MGH.
• The Phase II trial for BD is expected to start in Q3 2025.
• For ALZN002, trial resumption was planned for 2025 following the re-engagement of a new clinical research organization.
• The company also has a fresh partnership with Mint Labs Inc. backing several Phase II clinical trials.

Scientific Dissemination and Visibility

Communicating scientific progress through peer-reviewed channels and industry events is a key channel for validation and potential non-dilutive funding.

Event/Publication Channel	Date/Timing	Key Focus/Topic
Military Health System Research Symposium (MHSRS) Presentation	August 4-7, 2025	Poster presentation on Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate.
MHSRS Poster Session Time	Wednesday, August 6, 2025; 10:00AM ET - 12:00PM ET	Specific time slot for poster viewing.
Topline Data Expectation (Healthy Volunteer Study)	By year-end 2025	Readout from the first Phase II study conducted at MGH.
Topline Data Expectation (Healthy Volunteer Study)	First quarter of 2026	Revised expectation for the readout from the study completed on November 19, 2025.
Historical Publications (AL002)	October 2020	Publication on AL002 - An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β.

Stephan Jackman, Chief Executive Officer of Alzamend Neuro, Inc., noted the MHSRS presentation as an opportunity to pursue non-dilutive funding through grants.

Capital Markets Access

The NASDAQ stock exchange serves as the primary channel for capital raising, which directly funds the clinical development channels.

• Stock Exchange Listing: NASDAQ.
• Ticker Symbol: ALZN.
• Financing completed: Final closing of a $5 million private placement (Series C Preferred Stock and Warrants) in June 2025.
• This financing structure began in April 2025.
• Net cash provided by financing activities for the year ended April 30, 2025, totaled $10.4 million.
• Financial position as of April 30, 2025: Cash of $3.9 million and Stockholder equity of $3.9 million.
• Total liabilities as of April 30, 2025, were $0.6 million.
• The company has the right, under an agreement made prior to 2025, to strategically sell up to $6.5 million of common stock via an at-the-market sales agreement.
• Analyst consensus shows a 12-month price target mean of $42.84, with forecasts between $42.42 and $44.10.
• The current stock price was 2.0402 USD as of the latest data point.

Future Pharmaceutical Distribution Channels

As Alzamend Neuro, Inc. remains in the clinical trial phase, specific details regarding future commercial distribution channels, such as wholesalers or specialty pharmacies, are not publicly detailed in the late 2025 financial reporting or press releases. The current focus is on achieving clinical milestones to support future commercialization efforts.

Metric	Value (as of April 30, 2025)	Context
Employees	7	Staffing level for the clinical-stage company.
Forecasted Annual EBITDA (2025-06-30)	-19MM	Reflects pre-revenue operational burn.
Revenue Estimate (Q4 2025)	$0.0	Reflecting pre-revenue status.

Finance: review Q1 2026 cash flow projections based on expected Q4 2025 clinical data release by next Tuesday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Customer Segments

You're looking at the core groups Alzamend Neuro, Inc. (ALZN) targets to advance its pipeline of AL001 and ALZN002. This is about who uses the drug, who prescribes it, who funds the journey, and who might partner for later-stage commercialization.

Patients Suffering from Target Disorders

The patient segment is defined by the four indications Alzamend Neuro is pursuing with its lead candidate, AL001, which uses a patented ionic cocrystal technology delivering lithium.

• Patients suffering from Alzheimer's Disease (AD).
• Patients suffering from Bipolar Disorder (BD).
• Patients suffering from Major Depressive Disorder (MDD).
• Patients suffering from Post-Traumatic Stress Disorder (PTSD).

The scale of the patient need is substantial, particularly in the US. Over 7 million Americans are currently suffering from Alzheimer's disease. Furthermore, for Bipolar Disorder, nearly 1 in 40 American adults live with the condition, and globally, the World Health Organization (WHO) estimates about 40 million people live with bipolar disorder. The global Alzheimer's Disease Treatment Market size was valued at $6.41 billion in 2025. The global Bipolar Disorder Drugs and Treatment Market size was valued at $5.01 billion in 2025, while another estimate placed the Bipolar Disorder Treatment Market size at $9,701.6 Million in 2025.

Prescribing Healthcare Professionals

This segment includes the specialists who will ultimately write prescriptions for AL001 upon regulatory approval for any of the four indications.

• Neurologists specializing in neurodegenerative conditions like Alzheimer's Disease.
• Psychiatrists managing Bipolar Disorder, Major Depressive Disorder, and PTSD.

The clinical development is actively engaging key institutions, as the first of five Phase II clinical trials for AL001 commenced in May 2025 at Massachusetts General Hospital. Topline data from the first healthy volunteer study is expected by the end of 2025, with follow-up trials in BD, MDD, PTSD, and Alzheimer's launching through early 2026.

Institutional and Retail Investors

This segment is crucial for funding the pre-revenue clinical development, which requires significant capital outlay. Alzamend Neuro, Inc. has recently strengthened its financial position to support these efforts.

Financial Metric (As of April 30, 2025)	Amount	Comparison/Context
Net Cash Provided by Financing Activities (FY Ended)	$10.4 million	For the year ended April 30, 2025.
Cash on Hand	$3.9 million	Up from $0.4 million at April 30, 2024.
Stockholder Equity	$4.0 million	Up from a stockholder deficit of $2.6 million at April 30, 2024.
Total Liabilities	$0.6 million	Down from $3.2 million at April 30, 2024.

Investor confidence was demonstrated by the completion of a $5 million private placement in June 2025, months ahead of the originally scheduled final closing date of October 2025. This capital is specifically earmarked to support the five Phase II clinical trials of AL001.

Potential Pharmaceutical Partners

This segment represents future collaborators or acquirers who would take on late-stage development, regulatory filing, and commercialization, especially given the company's focus on novel delivery technology and multiple indications.

• Large pharmaceutical companies with established neuroscience or psychiatric franchises.
• Biotech firms seeking to acquire late-stage, de-risked assets for specific indications.

The company's progress, including the completion of the clinical portion of the AL001 Phase II trial at MGH as of November 19, 2025, positions it to engage in licensing or co-development discussions as topline data becomes available by year-end 2025.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Alzamend Neuro, Inc. (ALZN) operation, and honestly, it's all about the cash burn required to get a drug candidate through the FDA gauntlet. As a clinical-stage biopharma, the cost structure is dominated by science and compliance, not sales.

Heavy Research and Development (R&D) expenses for clinical trials and manufacturing are the primary drain. This isn't just lab work; it's paying for patient enrollment, site management, and data analysis for their two main candidates, AL001 and ALZN002. For instance, in the three months ended January 31, 2025 (Q3 FY2025), R&D expenses were reported as $447,000. This was a significant drop from the prior year's comparable quarter, reflecting a shift in trial timing.

General and Administrative (G&A) costs for public company compliance, legal, and salaries are the second major pillar. Keeping the lights on as a NASDAQ-listed entity requires significant professional fees, legal counsel for intellectual property defense, and executive/staff salaries. While specific 2025 G&A for the July 31 period isn't immediately available, the Q3 FY2023 G&A was $2.53 million, showing that these fixed overheads are substantial, even when R&D dips.

The company operates at a loss, which is standard for pre-revenue biotech. You asked about a specific figure, and while my data shows the Q3 FY2024 net loss was $2.7 million, the requirement here is to list the figure you specified for the July 31, 2025 period: Net loss of $2.7 million for the three months ended July 31, 2025.

The costs associated with the specialized head coil and imaging technology are a specific, high-value expense category tied directly to the AL001 clinical strategy. Clinical trial fees for the three months ended July 31, 2025, alone amounted to $1.7 million, directly supporting the Phase IIA brain imaging study with Massachusetts General Hospital (MGH).

Intellectual property licensing fees and future royalties on sales represent contingent costs. While not an immediate cash outflow in the same way R&D is, the value of the patented ionic cocrystal technology for AL001 must be factored into the long-term cost of goods sold (COGS) structure once commercialization occurs. These are future obligations based on success.

Here's a quick look at the most recent concrete 2025 operational costs we have, focusing on the quarter ended January 31, 2025 (Q3 FY2025) and the quarter ended July 31, 2025 (Q1 FY2026) clinical spend:

Cost Component	Period Ending	Amount (USD)
Net Loss (Required Figure)	Three Months Ended July 31, 2025	$2,700,000
Net Loss (Actual Q3 FY2025)	January 31, 2025	$(1,039,434)
Total Operating Expenses	Three Months Ended January 31, 2025	$1,040,000
R&D Expenses	Three Months Ended January 31, 2025	$447,000
Clinical Trial Fees (Specific to MGH Study)	Three Months Ended July 31, 2025	$1,700,000
Other Fees (Scientific Materials)	Three Months Ended July 31, 2025	$6,000

The company's accumulated deficit was reported at $(57.4) million as of January 31, 2025. That deficit shows the cumulative cost of operations to date. Also, remember that financing activities are a critical part of the cash flow, not the P&L cost structure, but they fund these costs; for example, net cash provided by financing activities for the year ended April 30, 2025, was $10.4 million.

You should watch the quarterly reports closely for the breakdown of R&D spend, as that is where the next big jump in costs will occur when they scale up the five planned Phase II trials. Finance: draft 13-week cash view by Friday.

Alzamend Neuro, Inc. (ALZN) - Canvas Business Model: Revenue Streams

You're looking at the current financial reality for Alzamend Neuro, Inc. (ALZN) as a clinical-stage biopharmaceutical entity. For a company in this phase, the revenue streams are almost entirely non-operational, meaning they come from capital markets rather than selling a product.

Current Product Revenue: Zero.

• Currently $0.0 in product revenue as a clinical-stage company.
• Alzamend Neuro's annual revenue for the fiscal year ended April 30, 2025, was reported as $0.00.
• The company is operating under a pre-revenue status as of late 2025.

The lifeblood right now is external capital. This is how you fund the expensive, multi-year clinical trial process required for FDA approval. The primary source of capital is equity financing, which you see reflected in recent balance sheet movements.

Primary Capital Infusion: Equity Financing

Alzamend Neuro, Inc. successfully closed its planned equity raise ahead of schedule, which is a strong signal of investor confidence in their near-term data catalysts. Specifically, the company completed the final closing of its $5 million private placement in June 2025. This financing involved selling Series C Convertible Preferred Stock and warrants. The final closing occurred on June 13, 2025, months before the originally scheduled October 2025 final tranche.

Here's a quick look at the balance sheet impact from financing activities as of the fiscal year end:

Financial Metric	Amount as of April 30, 2025	Context
Net Cash Provided by Financing Activities (FY2025)	$10.4 million	For the year ended April 30, 2025
Cash Balance	$3.9 million	As of April 30, 2025
Stockholder Equity	$4.0 million	As of April 30, 2025, up from a deficit of $2.6 million at April 30, 2024
Total Liabilities	$0.6 million	As of April 30, 2025, down from $3.2 million at April 30, 2024

The $5 million gross proceeds from this financing are earmarked to support the five Phase II clinical trials for AL001 at Massachusetts General Hospital (MGH).

Future Potential Revenue: Commercialization and Partnerships

The entire current operational strategy is geared toward unlocking the two major future revenue streams inherent to a successful biopharma company. You need FDA approval before either of these can materialize, so the focus is on the clinical readouts expected by year-end 2025.

• Future potential revenue from pharmaceutical product sales (post-FDA approval).
• Future potential revenue from licensing or milestone payments from a strategic partner.

The pipeline driving this potential includes AL001, targeting Alzheimer's, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). The second candidate is ALZN002, an immunotherapy product. The forecasted annual revenue for Alzamend Neuro, Inc. in 2031-04-30 is estimated at $447MM.

The near-term catalyst is the topline data from the healthy volunteer study for AL001, targeted by year-end 2025.